IVVD — Invivyd Inc.
NASDAQ · Healthcare · Biotechnology
$0.87
-$0.01 (-0.93%)
Invivyd Inc. (IVVD) is a biotechnology company listed on NASDAQ. It is led by William E. Duke Jr., M.B.A., based in 1601 Trapelo Road, Waltham, MA, United States, 02451, with about 99 employees. Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Latest reported IVVD revenue for 2025-09-30 was $13.1M. Net income was -$41.4M. Revenue was up 11.4% from 2025-06-30 to 2025-09-30. IVVD currently screens at market cap $85.8M.
Use this IVVD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IVVD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IVVD SEC filings page. Lician reads the product cache first so this HTML stays unique to Invivyd Inc. even when a live quote feed is slow.
About Invivyd Inc.
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
IVVD Key Statistics
Market Cap
$85.77M
Volume
9,567
Previous Close
$0.94
Day Range
$0.93 – $0.97
EPS
-$1.43
Revenue
$25.38M
Net Income
-$169.93M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-669.4%
Employees
99
IVVD Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $25.38M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$169.93M | -$198.64M | -$241.32M | -$226.79M |
| EPS (Diluted) | -$1.43 | -$1.81 | -$2.23 | -$5.32 |
Total Assets
$129.51M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$69.35M
Operating Cash Flow
-$170.49M
Free Cash Flow
$0.00
Invivyd Inc. Company Information
- CFO, Principal Accounting Officer & Principal Executive Officer
- William E. Duke Jr., M.B.A.
- Headquarters
- 1601 Trapelo Road, Waltham, MA, United States, 02451
- Website
- invivyd.com
- Phone
- 781 819 0080
- IPO / Founded
- 2021-08-06
- Sector
- Healthcare
- Industry
- Biotechnology